Clinical Trial Update: Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) [Phase 3]

View source ↗

Summary

A Phase 3 TALON study comparing brolucizumab 6 mg to aflibercept 2 mg in a treat-to-control regimen for age-related macular degeneration has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)
• EYLEA (Aflibercept)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2024-01-30